Dosing
Foundayo dosage chart: initiation, escalation, and interactions
Foundayo's milligram strengths are specific to orforglipron. They cannot be converted from Wegovy tablets, Rybelsus, or injection doses.
The labeled daily schedule
Start at 0.8 mg daily. The first two increases are to 2.5 mg and then 5.5 mg after at least 30 days at each preceding strength. Higher steps can be selected according to treatment response and tolerability; there is no requirement that every patient reach the highest strength.
A slow response does not justify taking two tablets, splitting a tablet, or moving up without a prescription. Starter doses introduce treatment and help address tolerability. Discuss persistent nausea or other symptoms before the next scheduled increase.
| Step | Daily dose | Timing |
|---|---|---|
| Initiation | 0.8 mg | At least 30 days |
| Second step | 2.5 mg | At least 30 days |
| Third step | 5.5 mg | At least 30 days |
| Optional further steps | 9 → 14.5 → 17.2 mg | At least 30 days at each current dose; clinician decision |
Sources: Foundayo prescribing information
Taking a tablet and handling interruptions
Take the tablet once daily with or without food and swallow it whole. Do not crush or chew it, and do not take more than one tablet per day. Unlike oral Wegovy, this product does not require the same morning fasting routine.
For a missed Foundayo dose, the label says to take it as soon as possible without doubling the next dose or taking more than one tablet in a day. After 7 or more consecutive missed doses, restart escalation at a lower dose with the prescriber. Product-specific directions matter more than a generic GLP-1 catch-up rule.
Sources: Foundayo prescribing information
Why the maximum may be lower
With a strong CYP3A4 inhibitor, the label limits Foundayo to 9 mg daily. It advises avoiding strong inhibitors that also inhibit OATP1B and avoiding strong CYP3A4 inducers. Concomitant simvastatin should not exceed 20 mg daily. These are examples of why a complete pharmacist review is necessary, not a list to manage on your own.
Bring prescription medicines, nonprescription products, and supplements to the review. Pregnancy, hepatic disease, insulin or sulfonylurea use, and contraception also affect treatment planning. Oral contraception needs a non-oral method or added barrier protection for 30 days after starting and each escalation.
Sources: Foundayo prescribing information
At least 30 days is a minimum, not a deadline
The chart describes the labeled order and minimum time at each strength. It does not instruct every patient to reach 17.2 mg on a fixed date. Further steps depend on response and tolerability, while interacting medicines may lower the maximum permitted dose. A follow-up should therefore assess the current clinical benefit and adverse effects before issuing the next strength.
For example, a person reaching a planned review date while struggling with persistent vomiting needs assessment of those symptoms rather than an automatic increase. Another person may be benefiting at an established strength and need a discussion about the continuing plan. Do not combine leftover tablets, split a tablet, or take an additional dose to simulate the next step. The label specifies one tablet per day, and a prescription should identify the actual strength to dispense.
Sources: Foundayo prescribing information
Why a new medicine can change the chart
Suppose a patient has been prescribed Foundayo and is then given another medicine that is a strong CYP3A4 inhibitor. The Foundayo label limits the daily dose to 9 mg with that class of inhibitor. Some inhibitor combinations and strong inducers are to be avoided. A patient should have the pharmacist identify the interaction and contact the prescriber, rather than independently reducing, skipping, or replacing either medicine.
Simvastatin has a separate concomitant dose limit in the Foundayo label. These examples show why medication review must continue after enrollment, not merely occur once during intake. Include short courses, nonprescription products, and supplements in the conversation. Inform any new prescribing clinician that you take Foundayo and provide the current dose. A chart printed before the medicine list changed may no longer describe the appropriate maximum.
Sources: Foundayo prescribing information
One missed tablet and a week-long gap are different
For a single missed dose, use the label's take-as-soon-as-possible instruction without doubling the next dose or exceeding one tablet in a day. If you are unsure whether today's tablet was already taken, a dose log is useful; uncertainty should not be resolved by taking another tablet just in case. A pharmacist can help apply the instruction to a confusing schedule.
Seven or more consecutive missed doses trigger a separate lower-dose restart instruction. Tell the clinician how long the gap lasted, the last strength used, why treatment stopped, and whether gastrointestinal symptoms remain. An old supply of the highest strength is not a restart plan. Keep the contraception precaution in the discussion when treatment is initiated or escalated, and confirm the written schedule before returning to regular daily dosing.
Sources: Foundayo prescribing information
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.